Approved boilerplate, executive bios, product fact sheets, brand assets, and media-ready language for Electrome Corporation and ActiPatch®.
Press inquiries
bioelectrictherapy@electrome.com — response within 1–2 business days.
Press releases
All official Electrome and ActiPatch announcements and coverage.
Brand assets
Logos, product imagery, executive headshots, and approved downloads.
Executive bios
Leadership team, advisors, and clinical board: approved bios.
For Press
Official Electrome announcements and recent press coverage.
April 21, 2026
Electrome Corporation is proud to announce the launch of ActiPatch®, our consumer‑facing bioelectric pain management platform, now available at painkiller.care.
Read releaseMarch 23, 2026
Electrome Corp announced the launch of its strategic partnership with BioElectronics Corp (BIEL), the pioneer in electromagnetic therapy devices and manufacturer of ActiPatch®, supporting the national launch of Electrome’s AI‑enabled bioelectric therapeutics platform and its flagship pain management solution, ActiPatch®.
Coverage: PR Newswire · Newswise · InfoMedD News · Street Insider
Read releaseJanuary 8, 2026
Electrome announces the LymeCure Research Study, a collaborative effort with Tulane University exploring bioelectric approaches to Lyme disease.
Coverage: BioSpace · The AI Journal · Yahoo Finance · Newswise
Read releaseOctober 10, 2025
Electrome Corporation launched The Human Electrome Project™ at an inaugural event in Cambridge, MA ‑ a nonprofit research initiative to map, model, and decode the bioelectric signaling systems that govern cellular behavior across all living organisms.
Read releaseElectrome Newsroom · 2026-05-08
Electrome Corporation publicly introduces electrome.com as the corporate face of its bioelectric medicine platform, anchored by FDA-cleared PSWT and ActiPatch®.
For Editors
Use verbatim when referencing Electrome Corporation in editorial coverage.
Short
Electrome is a bioelectric medicine company. We translate decades of peer-reviewed bioelectric science into FDA-cleared therapies and AI guided care, starting with chronic pain and inflammation.
Long
Electrome builds a vertically integrated bioelectric medicine platform: regulated devices, an AI care layer, and a data-grade clinical pipeline. Our first commercial product, ActiPatch®, is an FDA 510(k) cleared Pulsed Shortwave Therapy (PSWT) device for musculoskeletal pain. Beyond pain, our pipeline targets recovery, sleep, women's health, and other high-burden indications where bioelectric signaling is supported by published clinical evidence.
Products & Programs
Approved descriptions for the ActiPatch™ product line and Electrome programs.
Fact Sheet
ActiPatch® is an FDA 510(k) cleared (K192234), over-the-counter, drug-free wearable delivering 27.12 MHz pulsed shortwave therapy for adjunctive treatment of musculoskeletal pain. Each device provides 720 therapy hours.
Fact Sheet
ActiPatch® is an FDA 510(k) cleared (K192234), over-the-counter, drug-free wearable delivering 27.12 MHz pulsed shortwave therapy for adjunctive treatment of musculoskeletal pain. Each device provides 720 therapy hours.
Fact Sheet
Clinician-directed education and workflow information for qualified providers.
Fact Sheet
ActiPatch® is an FDA 510(k) cleared (K192234), over-the-counter, drug-free wearable delivering 27.12 MHz pulsed shortwave therapy for adjunctive treatment of musculoskeletal pain. Each device provides 720 therapy hours.
Fact Sheet
Electrome is a bioelectric medicine company. We translate decades of peer-reviewed bioelectric science into FDA-cleared therapies and AI guided care, starting with chronic pain and inflammation.
Leadership
Approved bios for Electrome leadership, advisors, and clinical board.

Erik A. Nilsen, PhD
Co-founder, Chief Executive Officer & Chief Technical Officer
Erik is a physicist and entrepreneur with advanced degrees in electrical engineering and mathematics who has spent 25+ years building bioelectric recording, control, and stimulation systems, securing multiple patents, contributing to multiple successful exits, and leading work across NIST ATP, NIH, and DARPA programs. As CEO, he sets the company's strategic direction and aligns its science, technology, and commercial roadmap around a single goal, making FDA-cleared bioelectric therapy broadly accessible. He brings the rare combination of deep technical fluency and the disciplined execution and capital formation needed to build Electrome into a leader in bioelectric medicine.

Nev Zubcevik, D.O.
Co-founder & Chief Medical Officer
Dr. Nev Zubcevik is a board-certified physician and former Harvard Medical School faculty member and Medical Director at Spaulding Rehabilitation Hospital, with deep expertise in musculoskeletal medicine, traumatic brain injury, concussion, and non-pharmacologic pain management. She is also a prolific inventor and researcher whose work spans bioelectric signaling, regenerative medicine, and chronic Lyme disease, including the LymeCure research collaboration with Tulane University, alongside peer-reviewed research on non-opioid recovery. At Electrome she directs clinical strategy, evidence generation, and the integration of bioelectric therapy into mainstream care pathways.

Danny Rubenstein
Chief Commercialization Officer
Danny Rubenstein is a commercial operator and strategic advisor with 40+ years across consumer products, food, and emerging businesses. He has held CEO, COO, and CFO roles, was an original partner in Naked Juice and has served as member of operating leadership teams with several startup and early stage companies. Danny applies a regenerative, whole systems approach, advising founders and leadership teams on strategy, growth and developing organizational capacity. At Electrome he leads commercialization strategy, channel development, and revenue execution.

Shari O'Connor, PharmD, MBA
Scientific Advisor, Clinical Marketing & Sales Development
Shari O'Connor is a neuroimmunology expert with 30+ years advancing brain and immune-system therapies, with board-level credentials in Neurology, Immunology, Nutrition, and Pharmacogenomics. Her published research spans encephalopathy, brain trauma, and immune-mediated neurological disease, and she has advised programs translating neuroscience research into pharmacy practice and clinical care. At Electrome she leads clinical marketing and sales development, translating the evidence base into the form clinicians, channel partners, and payer audiences evaluate and buy on. In a category where adoption is won on clinical credibility rather than promotion, her scientific standing is itself the commercial asset.

Samir S. Awad, MD
Medical Director
Dr. Samir S. Awad is Chief of Surgery and Operative Care Line Executive at the Michael E. DeBakey VA Medical Center in Houston, and Professor of Surgery and Vice-Chair for Surgical Quality and Safety at Baylor College of Medicine. A bioengineering graduate of Penn with surgical critical-care training at Michigan, he leads investigator-initiated clinical research across pain, wound healing, edema, and bioelectric therapeutics. At Electrome he serves as Medical Director, guiding FDA strategy and clinical evidence generation across the platform.

Wanni Davis, PhD, MBA
Licensing Advisor
Wanni Davis is a biotech strategist with 15+ years spanning translational science, venture development, and commercialization. As former Director of Industry Partnerships at Harvard-affiliated hospitals, she built and negotiated the industry alliances that move academic science out of the lab and into commercial development. At Electrome she serves as Licensing Advisor, leading partnerships, business development, and alliance operations across life sciences and biopharma, including partner agreements and the licensing pathway around Electrome's patent-pending portfolio.
Editorial Standards
Copy-safe language pulled verbatim from Electrome's source-of-truth entities.
What Electrome does
Electrome is a bioelectric medicine company. We translate decades of peer-reviewed bioelectric science into FDA-cleared therapies and AI guided care, starting with chronic pain and inflammation.
What ActiPatch® is
ActiPatch® is an FDA 510(k) cleared (K192234), over-the-counter, drug-free wearable delivering 27.12 MHz pulsed shortwave therapy for adjunctive treatment of musculoskeletal pain. Each device provides 720 therapy hours.
Bioelectric medicine (PSWT)
PSWT is a nonthermal, noncontact form of pulsed electromagnetic field (PEMF) therapy operating at 27.12 MHz. Unlike TENS, it is delivered by a self-contained wearable—no electrode pads or lead wires to manage. Designed to operate without perceptible heat or tingling from the device.
FDA-cleared device, ActiPatch®
ActiPatch® is an FDA 510(k) cleared (K192234), over-the-counter, drug-free wearable delivering 27.12 MHz pulsed shortwave therapy for adjunctive treatment of musculoskeletal pain. Each device provides 720 therapy hours.
Regulatory status: FDA 510(k) cleared.
Non-drug pain relief
PSWT is supported by decades of peer-reviewed research, including two double-blind, placebo/sham-controlled trials: a knee osteoarthritis RCT (Bagnato et al., Rheumatology 2016) reporting significant pain and function gains at one month, with 26% of patients stopping analgesics entirely and no adverse events; and a plantar fasciitis trial (Brook et al., J Foot Ankle Surg 2012) showing a significant reduction in first-step morning heel pain. A UK real-world registry of 5,000+ patients (Rawe & Kotak, Pain Management 2015) additionally reported, on a self-reported basis, a 57% mean pain reduction among the 65% who responded, with 93% still relieved at three months.
Downloads
Approved logos, product imagery, executive headshots, and documents. Items marked “Available by request” are released to credentialed press through the press contact flow.
Electrome corporate marks for editorial use.
ActiPatch® packaging and therapy device imagery.
Approved photography for leadership team members.
Approved Electrome documents available for the press.
ActiPatch® product sell sheets are released to credentialed press by request (source PDFs are gated behind the investor-documents portal).
Media Contact
bioelectrictherapy@electrome.com — response within 1–2 business days for interviews, statements, and asset requests.